APA
Majumder B., Baraneedharan U., Thiyagarajan S., Radhakrishnan P., Narasimhan H., Dhandapani M., Brijwani N., Pinto D. D., Prasath A., Shanthappa B. U., Thayakumar A., Surendran R., Babu G. K., Shenoy A. M., Kuriakose M. A., Bergthold G., Horowitz P., Loda M., Beroukhim R., Agarwal S., Sengupta S., Sundaram M. & Majumder P. K. (20160208). Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. : Nature communications.
Chicago
Majumder Biswanath, Baraneedharan Ulaganathan, Thiyagarajan Saravanan, Radhakrishnan Padhma, Narasimhan Harikrishna, Dhandapani Muthu, Brijwani Nilesh, Pinto Dency D, Prasath Arun, Shanthappa Basavaraja U, Thayakumar Allen, Surendran Rajagopalan, Babu Govind K, Shenoy Ashok M, Kuriakose Moni A, Bergthold Guillaume, Horowitz Peleg, Loda Massimo, Beroukhim Rameen, Agarwal Shivani, Sengupta Shiladitya, Sundaram Mallikarjun and Majumder Pradip K. 20160208. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. : Nature communications.
Harvard
Majumder B., Baraneedharan U., Thiyagarajan S., Radhakrishnan P., Narasimhan H., Dhandapani M., Brijwani N., Pinto D. D., Prasath A., Shanthappa B. U., Thayakumar A., Surendran R., Babu G. K., Shenoy A. M., Kuriakose M. A., Bergthold G., Horowitz P., Loda M., Beroukhim R., Agarwal S., Sengupta S., Sundaram M. and Majumder P. K. (20160208). Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. : Nature communications.
MLA
Majumder Biswanath, Baraneedharan Ulaganathan, Thiyagarajan Saravanan, Radhakrishnan Padhma, Narasimhan Harikrishna, Dhandapani Muthu, Brijwani Nilesh, Pinto Dency D, Prasath Arun, Shanthappa Basavaraja U, Thayakumar Allen, Surendran Rajagopalan, Babu Govind K, Shenoy Ashok M, Kuriakose Moni A, Bergthold Guillaume, Horowitz Peleg, Loda Massimo, Beroukhim Rameen, Agarwal Shivani, Sengupta Shiladitya, Sundaram Mallikarjun and Majumder Pradip K. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. : Nature communications. 20160208.